Recruiting
Cell Free DNA for the Diagnosis and Treatment in Early NSCLC
About this study
The aim of the study is to evaluate whether peripheral circulating cell-free tumor DNA (cfDNA) can aid screening of recurrence after complete resection of early stage non-small cell lung cancer.
- Condition
- Non-small Cell Lung Cancer
- Sponsor
- Samsung Medical Center
Who can join
- Age
- 18 to 90 years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 7
- Minimum age: 18 years
- Maximum age: 90 years
- Study condition: Non-small Cell Lung Cancer
- All subjects need to sign the informed consent form
- All subjects have Non-small cell lung cancer which suspected on chest CT or confirmed pathologically preoperatively.
- Non-small cell lung cancer have to confirmed pathologically after operation
- Clinical stage I - IIIA by AJCC 7th staging system
Exclusion 4
- Have been undergone chemotherapy or radiotherapy due to non-small call lung cancer
- Have been diagnosed any type of cancer other than cancer of skin, thyroid, uterine cervix with 3 years before enrollment
- Recurrent lung cancer
- Stage IIIB, IV by AJCC 7th staging system
Where
1 site, 1 recruiting
Samsung Medical Center
Seoul, South Korea
Contact
-
Jhingook Kim, MD
+82-2-3410-3483 jkimsmc@skku.edu
Potential match only. Final eligibility is determined by the study team.